A large population-based study has strongly implicated a lowered risk of prostate cancer among users of VPA [41], and recent clinical trials of the HDAC inhibitors vorinostat, romidepsin, and panobinostat have provided cautious optimism towards improved outcomes for CRPC patients [42]. This evidence concerns the gene HDAC9 and prostate carcinoma.